Cat. No.: HY-13685

Miltefosine

Name: Miltefosine
Brand: MedChemExpress
SKU: HY-13685
Price: 50.00 USD
Availability: InStock
Rating: 5 (15 reviews)

(Synonyms: HePC; Hexadecyl phosphocholine)

15 Cited Publications

Avis client

Based on 15 publication(s) in Google Scholar

Miltefosine is a broad spectrum antimicrobial, anti-leishmanial, phospholipid agent acting by inhibiting the PI3K/Akt activity. Miltefosine is an inhibitor of CTP-phosphocholine cytidyltransferase (CCT).

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.92%
CAS No.: 58066-85-6
Formule: C₂₁H₄₆NO₄P
Masse moléculaire:407.57

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Miltefosine Chemical Structure

CAS No.: 58066-85-6

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Essai clinique
Chemical Information
Publications (15)
Solvant et solubilité
- In Vitro
- In Vivo
Protocole
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Miltefosine is a broad spectrum antimicrobial, anti-leishmanial, phospholipid agent acting by inhibiting the PI3K/Akt activity^[1]^[2]^[3]^[4]. Miltefosine is an inhibitor of CTP-phosphocholine cytidyltransferase (CCT)^[5].

IC₅₀ & Target^[1]

HIV-1

Voir tous les produits spécifiques à Isoform Akt :

Voir tous les produits spécifiques à Isoform HIV :

Voir tous les produits spécifiques à Isoform Parasite :

Cellular Effect

Cell Line	Type	Value	Description	References
786-0	IC₅₀	>100 μM Compound: MIL	Cytotoxicity against human 786-O cells assessed as decrease in mitochondrial viability after 6 hrs by CMXRos staining based assay Cytotoxicity against human 786-O cells assessed as decrease in mitochondrial viability after 6 hrs by CMXRos staining based assay	[PMID: 29407968]
A2780	IC₅₀	8.87 μM Compound: HPC, miltefosine	Cytotoxicity against human A2780 cells after 24 hrs by MTT method Cytotoxicity against human A2780 cells after 24 hrs by MTT method	[PMID: 25698517]
A-431	IC₅₀	53.7 μM Compound: miltefosine	Cytotoxicity against human A431 cells after 24 hrs by MTT assay Cytotoxicity against human A431 cells after 24 hrs by MTT assay	[PMID: 20039643]
A-431	IC₅₀	12 μM Compound: Miltefosine	Cytotoxic activity against human A431 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay Cytotoxic activity against human A431 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay	[PMID: 25814031]
A549	IC₅₀	44.7 μM Compound: HPC, miltefosine	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 19762125]
A549	IC₅₀	9.6 μM Compound: 1, HePC, Miltex, Impavido	Inhibition of Akt phosphorylation in insulin-stimulated human A549 cells treated 2 hrs before insulin stimulation measured after 30 mins by ELISA Inhibition of Akt phosphorylation in insulin-stimulated human A549 cells treated 2 hrs before insulin stimulation measured after 30 mins by ELISA	[PMID: 22138309]
A549	IC₅₀	9.7 μM Compound: 1, HePC, Miltex, Impavido	Cytotoxicity against human A549 cells after 24 hrs by FACS analysis Cytotoxicity against human A549 cells after 24 hrs by FACS analysis	[PMID: 22138309]
A549	IC₅₀	9.6 μM Compound: 1, HePC	Inhibition of Akt phosphorylation in human insulin-stimulated A549 cells incubated for 2 hrs prior to insulin-induction measured after 30 mins by ELISA Inhibition of Akt phosphorylation in human insulin-stimulated A549 cells incubated for 2 hrs prior to insulin-induction measured after 30 mins by ELISA	[PMID: 23415083]
A549	IC₅₀	9.7 μM Compound: 1, HePC	Cytotoxicity against human A549 cells by flow cytometric analysis Cytotoxicity against human A549 cells by flow cytometric analysis	[PMID: 23415083]
A549	IC₅₀	8.6 μM Compound: HPC	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 23792315]
A549	IC₅₀	8.5 μM Compound: Miltefosine	Cytotoxic activity against human A549 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay Cytotoxic activity against human A549 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay	[PMID: 25814031]
A549	IC₅₀	>100 μM Compound: MIL	Cytotoxicity against human A549 cells after 48 hrs by CellTiter-Glo assay Cytotoxicity against human A549 cells after 48 hrs by CellTiter-Glo assay	[PMID: 29407968]
BJ	IC₅₀	>50 μM Compound: Miltefosine	Cytotoxicity against human BJ cells after 24 hrs by redox-sensitive dye based fluorescent assay Cytotoxicity against human BJ cells after 24 hrs by redox-sensitive dye based fluorescent assay	[PMID: 33091607]
BMDM	IC₅₀	≥200 μM Compound: Miltefosine	Cytotoxicity against mouse BMDM after 96 hrs by MTT assay Cytotoxicity against mouse BMDM after 96 hrs by MTT assay	[PMID: 23719286]
CCRF-CEM	IC₅₀	13.5 μM Compound: HPC, miltefosine	Cytotoxicity against human CCRF-CEM cells after 72 hrs by MTT assay Cytotoxicity against human CCRF-CEM cells after 72 hrs by MTT assay	[PMID: 19762125]
CCRF-CEM	IC₅₀	20.7 μM Compound: HPC	Cytotoxicity against human CCRF-CEM cells after 72 hrs by MTT assay Cytotoxicity against human CCRF-CEM cells after 72 hrs by MTT assay	[PMID: 23792315]
DU-145	IC₅₀	24.92 μM Compound: miltefosine	In vitro cytotoxic activity against prostate carcinoma (DU-145) cells assayed by inhibition of [3H]-labeled thymidine incorporation In vitro cytotoxic activity against prostate carcinoma (DU-145) cells assayed by inhibition of [3H]-labeled thymidine incorporation	[PMID: 11728191]
DU-145	IC₅₀	25.78 μM Compound: Miltefosine	Antiproliferative activity against human DU145 cells assessed as inhibition of cell proliferation incubated for 18 hrs followed by MTT addition for 4 hrs by MTT assay Antiproliferative activity against human DU145 cells assessed as inhibition of cell proliferation incubated for 18 hrs followed by MTT addition for 4 hrs by MTT assay	[PMID: 25128666]
Erythrocyte	EC₅₀	30 μM Compound: HPC, miltefosine	Toxicity in human erythrocytes assessed as hemolysis after 1 hr Toxicity in human erythrocytes assessed as hemolysis after 1 hr	[PMID: 19762125]
HeLa	IC₅₀	41.6 μM Compound: HPC, miltefosine	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 19762125]
HeLa	IC₅₀	128.9 μM Compound: HPC	Cytotoxicity against human HeLa cells Cytotoxicity against human HeLa cells	[PMID: 19818608]
HeLa	IC₅₀	74.4 μM Compound: HPC	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 23792315]
HeLa	IC₅₀	16.5 μM Compound: Miltefosine	Cytotoxic activity against human HeLa cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay Cytotoxic activity against human HeLa cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay	[PMID: 25814031]
HepG2	CC₅₀	50.3 μM Compound: Miltefosine	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 22608675]
HepG2	IC₅₀	>25 μg/mL Compound: Miltefosine	Cytotoxicity against human HepG2 cells after 48 hrs by neutral red Cytotoxicity against human HepG2 cells after 48 hrs by neutral red	[PMID: 23891181]
HepG2	CC₅₀	50.3 μM Compound: Miltefosine	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 24080103]
HepG2	CC₅₀	50.3 μM Compound: Miltefosine	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 25559208]
HepG2	IC₅₀	26.3 μM Compound: Miltefosine	Cytotoxic activity against human HepG2 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay Cytotoxic activity against human HepG2 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay	[PMID: 25814031]
HepG2	CC₅₀	50.3 μM Compound: Miltefosine	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 25846065]
HepG2	CC₅₀	85 μM Compound: Miltefosine	Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 29885575]
HepG2	CC₅₀	85 μM Compound: Miltefosine	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30092366]
HepG2	CC₅₀	85 μM Compound: Miltefosine	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 30655943]
HepG2	CC₅₀	85 μM Compound: Miltefosine	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 32292551]
HepG2	CC₅₀	85 μM Compound: Miltefosine	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 32652409]
HepG2	CC₅₀	85 μM Compound: Miltefosine	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 32795774]
HepG2	EC₅₀	>75 μM Compound: Miltefosine	Cytotoxicity against human HepG2 cells incubated for 24 hrs by crystal violet staining based assay Cytotoxicity against human HepG2 cells incubated for 24 hrs by crystal violet staining based assay	[PMID: 33945281]
HepG2	CC₅₀	78.62 μM Compound: Miltefosine	Cytotoxicity against human HepG2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay	[PMID: 35814931]
HepG2	CC₅₀	>75 μM Compound: Miltefosine	Cytotoxicity against human HepG2 cells assessed as reduction in cell proliferation measured after 72 hrs by crystal violet staining based analysis Cytotoxicity against human HepG2 cells assessed as reduction in cell proliferation measured after 72 hrs by crystal violet staining based analysis	[PMID: 36075146]
HepG2	CC₅₀	>75 μM Compound: Miltefosine	Cytotoxicity against human HepG2 cells assessed as reduction in cell proliferation measured after 72 hrs by crystal violet staining based analysis Cytotoxicity against human HepG2 cells assessed as reduction in cell proliferation measured after 72 hrs by crystal violet staining based analysis	[PMID: 36332553]
HepG2	CC₅₀	51.6 μM Compound: Miltefosine	Cytotoxicity against human HepG2 cells incubated for 48 hrs by PI staining based flow cytometric analysis Cytotoxicity against human HepG2 cells incubated for 48 hrs by PI staining based flow cytometric analysis	[PMID: 38461679]
HFL1	IC₅₀	203.4 μM Compound: HPC	Cytotoxicity against human HFL1 cells Cytotoxicity against human HFL1 cells	[PMID: 19818608]
HL-60	IC₅₀	20.4 μM Compound: Miltefosine	Cytotoxicity measured in HL-60 leukemic cells after a 24 hr incubation period. Cytotoxicity measured in HL-60 leukemic cells after a 24 hr incubation period.	[PMID: 7707324]
HT-29	IC₅₀	6.15 μM Compound: miltefosine	In vitro cytotoxic activity against colon adenocarcinoma (HT-29) cells assayed by inhibition of [3H]-labeled thymidine incorporation In vitro cytotoxic activity against colon adenocarcinoma (HT-29) cells assayed by inhibition of [3H]-labeled thymidine incorporation	[PMID: 11728191]
HT-29	IC₅₀	48.6 μM Compound: miltefosine	Cytotoxicity against human HT-29 cells after 24 hrs by MTT assay Cytotoxicity against human HT-29 cells after 24 hrs by MTT assay	[PMID: 20039643]
HuT78	IC₅₀	67.24 μM Compound: HPC, miltefosine	Cytotoxicity against human HUT78 cells after 24 hrs by MTS method Cytotoxicity against human HUT78 cells after 24 hrs by MTS method	[PMID: 25698517]
HUVEC	IC₅₀	>100 μM Compound: HPC	Cytotoxicity against HUVEC after 72 hrs by MTT assay Cytotoxicity against HUVEC after 72 hrs by MTT assay	[PMID: 23792315]
HUVEC	CC₅₀	54.3 μM Compound: Miltefosine	Cytotoxicity against HUVEC cells assessed as reduction in cell viability Cytotoxicity against HUVEC cells assessed as reduction in cell viability	[PMID: 34116159]
J774	CC₅₀	135.9 μM Compound: M	Cytotoxicity against mouse J774 cells assessed as reduction of cell viability after 24 hrs by resazurin dye-based fluorometric analysis Cytotoxicity against mouse J774 cells assessed as reduction of cell viability after 24 hrs by resazurin dye-based fluorometric analysis	[PMID: 24151871]
J774	IC₅₀	20.9 μM Compound: M	Leishmanicidal activity against intracellular amastigote stage of Leishmania amazonensis MHOM/Br/79/Maria infected in mouse J774 cells assessed as reduction of parasite load after 48 hrs by resazurin dye-based fluorometric analysis Leishmanicidal activity against intracellular amastigote stage of Leishmania amazonensis MHOM/Br/79/Maria infected in mouse J774 cells assessed as reduction of parasite load after 48 hrs by resazurin dye-based fluorometric analysis	[PMID: 24151871]
J774	IC₅₀	23.7 μM Compound: M	Leishmanicidal activity against intracellular amastigote stage of Leishmania infantum MCAN/ES/96/BCN150 infected in mouse J774 cells assessed as reduction of parasite load after 48 hrs by resazurin dye-based fluorometric analysis Leishmanicidal activity against intracellular amastigote stage of Leishmania infantum MCAN/ES/96/BCN150 infected in mouse J774 cells assessed as reduction of parasite load after 48 hrs by resazurin dye-based fluorometric analysis	[PMID: 24151871]
J774	CC₅₀	163.6 μM Compound: Miltefosine	Cytotoxicity against mouse J774 cells assessed as reduction in cell viability after 24 hrs by resazurin fluorescence assay Cytotoxicity against mouse J774 cells assessed as reduction in cell viability after 24 hrs by resazurin fluorescence assay	[PMID: 24953952]
J774	IC₅₀	20.9 μM Compound: Miltefosine	Antileishmanial activity against amastigote form of Leishmania amazonensis MHOM/Br/79/Maria infected in mouse J774 cells assessed as reduction in intracellular amastigotes compound treated for 48 hrs followed by 3 days incubation for transformation by res Antileishmanial activity against amastigote form of Leishmania amazonensis MHOM/Br/79/Maria infected in mouse J774 cells assessed as reduction in intracellular amastigotes compound treated for 48 hrs followed by 3 days incubation for transformation by res	[PMID: 24953952]
J774	IC₅₀	23.7 μM Compound: Miltefosine	Antileishmanial activity against amastigote form of Leishmania infantum MCAN/ES/96/BCN150 infected in mouse J774 cells assessed as reduction in intracellular amastigotes compound treated for 48 hrs followed by 3 days incubation for transformation by resaz Antileishmanial activity against amastigote form of Leishmania infantum MCAN/ES/96/BCN150 infected in mouse J774 cells assessed as reduction in intracellular amastigotes compound treated for 48 hrs followed by 3 days incubation for transformation by resaz	[PMID: 24953952]
J774	CC₅₀	136.4 μM Compound: Miltefosine	Cytotoxicity against mouse J774 cells assessed as reduction of cell viability after 48 hrs by resazurin dye-based fluorometric method Cytotoxicity against mouse J774 cells assessed as reduction of cell viability after 48 hrs by resazurin dye-based fluorometric method	[PMID: 27318121]
J774	IC₅₀	16.5 μM Compound: Miltefosine	Leishmanicidal activity against amastigote form of Leishmania amazonensis MHOM/Br/79/Maria infected in mouse J774 cells after 48 hrs by resazurin dye-based fluorometric method Leishmanicidal activity against amastigote form of Leishmania amazonensis MHOM/Br/79/Maria infected in mouse J774 cells after 48 hrs by resazurin dye-based fluorometric method	[PMID: 27318121]
J774	IC₅₀	58.1 μM Compound: Miltefosine	Leishmanicidal activity against amastigote form of Leishmania infantum MCAN/ES/96/BCN150 infected in mouse J774 cells after 48 hrs by resazurin dye-based fluorometric method Leishmanicidal activity against amastigote form of Leishmania infantum MCAN/ES/96/BCN150 infected in mouse J774 cells after 48 hrs by resazurin dye-based fluorometric method	[PMID: 27318121]
J774	CC₅₀	55.7 μM Compound: miltefosine	Cytotoxicity against mouse J774 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against mouse J774 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28059524]
J774	CC₅₀	136.4 μM Compound: Miltefosine	Cytotoxicity against mouse J774 cells assessed as reduction in cell viability after 48 hrs by resazurin dye-based fluorometric analysis Cytotoxicity against mouse J774 cells assessed as reduction in cell viability after 48 hrs by resazurin dye-based fluorometric analysis	[PMID: 30840453]
J774	CC₅₀	135.9 μM Compound: Miltefosine	Cytotoxicity against mouse J774 cells assessed as reduction in cell viability after 24 hrs by resazurin dye based assay Cytotoxicity against mouse J774 cells assessed as reduction in cell viability after 24 hrs by resazurin dye based assay	[PMID: 33901901]
J774	CC₅₀	72.35 μM Compound: Miltefosine	Cytotoxicity against mouse macrophage J774 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay Cytotoxicity against mouse macrophage J774 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay	[PMID: 35814931]
J774	CC₅₀	50 μM Compound: Miltefosine	Cytotoxicity against mouse J774 cells after 24 hrs by WST-1 assay Cytotoxicity against mouse J774 cells after 24 hrs by WST-1 assay	[PMID: 36508970]
J774	CC₅₀	68.01 μM Compound: Miltefosine	Cytotoxicity against mouse J774 macrophage incubated for 72 hrs by MTT assay Cytotoxicity against mouse J774 macrophage incubated for 72 hrs by MTT assay	[PMID: 37290183]
J774.1	CC₅₀	94.6 μM Compound: Miltefosine	Cytotoxicity against mouse J774.1 cells after 72 hrs by MTT assay Cytotoxicity against mouse J774.1 cells after 72 hrs by MTT assay	[PMID: 24080103]
J774.1	IC₅₀	90.4 μM Compound: Miltefosine	Cytotoxicity against mouse J774A.1 cells after 72 hrs by MTT assay Cytotoxicity against mouse J774A.1 cells after 72 hrs by MTT assay	[PMID: 25846065]
J774.1	CC₅₀	89.21 μM Compound: 10	Cytotoxicity against mouse J774.1 cells Cytotoxicity against mouse J774.1 cells	[PMID: 37859724]
J774.A1	IC₅₀	33.9 μg/mL Compound: miltefosine	Antiamastigote activity against Leishmania donovani MHOM IN/Dd8 in mouse J-774A.1 cells by luciferase reporter gene assay after 72 hrs Antiamastigote activity against Leishmania donovani MHOM IN/Dd8 in mouse J-774A.1 cells by luciferase reporter gene assay after 72 hrs	[PMID: 17306422]
J774.A1	IC₅₀	5 μg/mL Compound: miltefosine	Antileishmanial activity against Leishmania donovani amastigote infected in mouse J774A1 cells expressing green fluorescence protein by flow cytometry Antileishmanial activity against Leishmania donovani amastigote infected in mouse J774A1 cells expressing green fluorescence protein by flow cytometry	[PMID: 19339182]
J774.A1	CC₅₀	31.31 μg/mL Compound: Miltefosine	Cytotoxicity against mouse J774A1 cells after 72 hrs by MTT assay Cytotoxicity against mouse J774A1 cells after 72 hrs by MTT assay	[PMID: 20199824]
J774.A1	IC₅₀	12.11 μg/mL Compound: Miltefosine	Antileishmanial activity against Leishmania donovani MHOM/IN/Dd8 amastigote carrying firefly luciferase gene infected in mouse J774A1 cells assessed as relative luminescence unit after 72 hrs Antileishmanial activity against Leishmania donovani MHOM/IN/Dd8 amastigote carrying firefly luciferase gene infected in mouse J774A1 cells assessed as relative luminescence unit after 72 hrs	[PMID: 20199824]
J774.A1	CC₅₀	3.23 μM Compound: Miltefosine	Cytotoxicity against mouse J774A1 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against mouse J774A1 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 21385661]
J774.A1	CC₅₀	94.6 μM Compound: Miltefosine	Cytotoxicity against mouse J774A1 cells after 72 hrs by MTT assay Cytotoxicity against mouse J774A1 cells after 72 hrs by MTT assay	[PMID: 22608675]
J774.A1	CC₅₀	12.42 μM Compound: Miltefosine	Cytotoxicity against mouse J774A1 cells after 72 hrs by MTT assay Cytotoxicity against mouse J774A1 cells after 72 hrs by MTT assay	[PMID: 23611626]
J774.A1	IC₅₀	8.4 μM Compound: Miltefosine	Antileishmanial activity against amastigotes of Leishmania donovani MHOM/IN/60/Dd8 infected in mouse J-774A.1 cells after 72 hrs by luciferase reporter gene assay Antileishmanial activity against amastigotes of Leishmania donovani MHOM/IN/60/Dd8 infected in mouse J-774A.1 cells after 72 hrs by luciferase reporter gene assay	[PMID: 23611626]
J774.A1	IC₅₀	12.5 μM Compound: Miltefosine	Antileishmanial activity against Leishmania donovani amastigotes infected in mouse J774A1 cells after 72 hrs by luciferase reporter gene assay Antileishmanial activity against Leishmania donovani amastigotes infected in mouse J774A1 cells after 72 hrs by luciferase reporter gene assay	[PMID: 23910597]
J774.A1	IC₅₀	8.4 μM Compound: Miltefosine	Antileishmanial activity against Leishmania donovani MHOM/IN/80/Dd8 amastigotes infected in mouse J774A1 cells assessed as parasite growth inhibition after 72 hrs by luciferase reporter gene assay Antileishmanial activity against Leishmania donovani MHOM/IN/80/Dd8 amastigotes infected in mouse J774A1 cells assessed as parasite growth inhibition after 72 hrs by luciferase reporter gene assay	[PMID: 24095747]
J774.A1	IC₅₀	8.1 μM Compound: MF	Antileishmanial activity against intracellular amastigote stage of Leishmania donovani MHOM/IN/80/Dd8 expressing luciferase firefly reporter gene infected in mouse J774A1 cells after 72 hrs by luminescence assay Antileishmanial activity against intracellular amastigote stage of Leishmania donovani MHOM/IN/80/Dd8 expressing luciferase firefly reporter gene infected in mouse J774A1 cells after 72 hrs by luminescence assay	[PMID: 24314395]
J774.A1	IC₅₀	25.35 μM Compound: Miltefosine	Induction of nitric oxide production in mouse J774A1 cells infected with Leishmania donovani after 24 hrs by Griess reagent based spectrophotometric analysis Induction of nitric oxide production in mouse J774A1 cells infected with Leishmania donovani after 24 hrs by Griess reagent based spectrophotometric analysis	[PMID: 24635539]
J774.A1	IC₅₀	8.4 μM Compound: Miltefosine	Antileishmanial activity against intracellular amastigote form of Leishmania donovani MHOM/IN/80/Dd8 expressing luciferase gene infected in mouse J774A1 cells after 72 hrs by luminescence analysis Antileishmanial activity against intracellular amastigote form of Leishmania donovani MHOM/IN/80/Dd8 expressing luciferase gene infected in mouse J774A1 cells after 72 hrs by luminescence analysis	[PMID: 24635539]
J774.A1	IC₅₀	8.4 μM Compound: Miltefosine	Antiamastigote activity against promastigote stage of Leishmania donovani MHOM/IN/80/Dd8 expressing luciferase firefly reporter gene infected in mouse J774A1 cells after 72 hrs by luminescence assay Antiamastigote activity against promastigote stage of Leishmania donovani MHOM/IN/80/Dd8 expressing luciferase firefly reporter gene infected in mouse J774A1 cells after 72 hrs by luminescence assay	[PMID: 24858541]
J774.A1	IC₅₀	8.1 μM Compound: MF	Antileishmanial activity against amastigote stage of Leishmania donovani MHOM/IN/80/Dd8 infected in mouse J-774A.1 cells after 72 hrs by luciferase reporter gene assay Antileishmanial activity against amastigote stage of Leishmania donovani MHOM/IN/80/Dd8 infected in mouse J-774A.1 cells after 72 hrs by luciferase reporter gene assay	[PMID: 24900613]
J774.A1	IC₅₀	4.2 μM Compound: Miltefosine	Antileishmanial activity against intracellular amastigote stage of Leishmania infantum MHOM/MA/67/ITMAP-263 expressing luciferase infected in mouse J774A1 cells assessed as inhibition of metabolic activity after 120 hrs by luminescence assay Antileishmanial activity against intracellular amastigote stage of Leishmania infantum MHOM/MA/67/ITMAP-263 expressing luciferase infected in mouse J774A1 cells assessed as inhibition of metabolic activity after 120 hrs by luminescence assay	[PMID: 25846065]
J774.A1	IC₅₀	8.2 μM Compound: Miltefosine	Antileishmanial activity against Leishmania donovani MHOM/IN/80/Dd8 expressing luciferase reporter gene infected in mouse J-774A1 cells assessed as inhibition of amastigote stage formation incubated for 72 hrs by luminometry Antileishmanial activity against Leishmania donovani MHOM/IN/80/Dd8 expressing luciferase reporter gene infected in mouse J-774A1 cells assessed as inhibition of amastigote stage formation incubated for 72 hrs by luminometry	[PMID: 26318065]
J774.A1	CC₅₀	14.3 μM Compound: MF	Cytotoxicity against mouse J774A.1 cells after 72 hrs by MTT assay Cytotoxicity against mouse J774A.1 cells after 72 hrs by MTT assay	[PMID: 26840364]
J774.A1	IC₅₀	>50 μM Compound: Miltefosine	Cytotoxicity against mouse J774.A1 cells after 72 hrs by MTS assay Cytotoxicity against mouse J774.A1 cells after 72 hrs by MTS assay	[PMID: 28835791]
J774.A1	CC₅₀	73.7 μM Compound: Miltefosine	Cytotoxicity against mouse J774A.1 cells Cytotoxicity against mouse J774A.1 cells	[PMID: 29126735]
J774.A1	CC₅₀	40.5 μM Compound: Miltefosine	Cytotoxicity against mouse J774A1 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against mouse J774A1 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 29549842]
J774.A1	CC₅₀	56 μM Compound: Miltefosine	Cytotoxicity against mouse J774A.1 cells after 48 hrs by MTT assay Cytotoxicity against mouse J774A.1 cells after 48 hrs by MTT assay	[PMID: 29793211]
J774.A1	CC₅₀	12.42 μM Compound: Miltefosine	Cytotoxicity against mouse J774A.1 cells after 2 hrs by MTT assay Cytotoxicity against mouse J774A.1 cells after 2 hrs by MTT assay	[PMID: 30108893]
J774.A1	CC₅₀	55 μM Compound: Miltefosine	Cytotoxicity against mouse J774A1 cells assessed as cell viability incubated for 48 hrs by MTT assay Cytotoxicity against mouse J774A1 cells assessed as cell viability incubated for 48 hrs by MTT assay	[PMID: 31098003]
J774.A1	IC₅₀	>120 μM Compound: Miltefosine	Cytotoxicity against mouse J774A.1 cells incubated for 72 hrs by CellTiter 96 AQueous One solution cell proliferation assay Cytotoxicity against mouse J774A.1 cells incubated for 72 hrs by CellTiter 96 AQueous One solution cell proliferation assay	[PMID: 32281798]
J774.A1	CC₅₀	53.33 μM Compound: Miltefosine	Cytotoxicity against mouse J774A1 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against mouse J774A1 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 33479698]
J774.A1	CC₅₀	53.33 μM Compound: Miltefosine	Cytotoxicity against mouse J774A.1 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against mouse J774A.1 cells assessed as reduction in cell viability by MTT assay	[PMID: 36565533]
J774.A1	CC₅₀	52.1 μM Compound: Miltefosine	Cytotoxicity against mouse J774.A1 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay Cytotoxicity against mouse J774.A1 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay	[PMID: 37360388]
J774.A1	CC₅₀	53.33 μM Compound: Miltefosine	Cytotoxicity against mouse J774.A1 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against mouse J774.A1 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 37837672]
J774.A1	EC₅₀	>100000 nM Compound: Miltefosine	Cytotoxicity against mouse J774.A1 cells assessed as reduction in cell survival measured after 96 hrs by SYBR Green II dye based analysis Cytotoxicity against mouse J774.A1 cells assessed as reduction in cell survival measured after 96 hrs by SYBR Green II dye based analysis	[PMID: 38722757]
Jurkat	IC₅₀	10 μM Compound: HPC, miltefosine	Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay	[PMID: 19762125]
Jurkat	IC₅₀	33.35 μM Compound: Miltefosine	Cytotoxicity against human Jurkat cells assessed as live cells in neubauer chamber after 24 hrs by trypan blue assay Cytotoxicity against human Jurkat cells assessed as live cells in neubauer chamber after 24 hrs by trypan blue assay	[PMID: 21571403]
KB	CC₅₀	3.23 μM Compound: Miltefosine	Cytotoxicity against human KB cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human KB cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 23031588]
KB	CC₅₀	3.23 μM Compound: Miltefosine, Impavido	Cytotoxicity against human KB cells after 72 hrs by MTT assay Cytotoxicity against human KB cells after 72 hrs by MTT assay	[PMID: 23177254]
KB	CC₅₀	3.2 μM Compound: Miltefosine	Cytotoxicity against human KB cells after 72 hrs by MTT assay Cytotoxicity against human KB cells after 72 hrs by MTT assay	[PMID: 23182089]
KB	CC₅₀	54.1 μM Compound: Miltefosine	Cytotoxicity in human KB cells assessed as cell viability incubated for 72 hrs by MTT assay Cytotoxicity in human KB cells assessed as cell viability incubated for 72 hrs by MTT assay	[PMID: 26318065]
L6	IC₅₀	0.23 μg/mL Compound: Miltefosin	Antitrypanosomal activity against Trypanosoma cruzi Tulahuen C2C4 trypomastigotes infected in rat L6 cells after 4 days Antitrypanosomal activity against Trypanosoma cruzi Tulahuen C2C4 trypomastigotes infected in rat L6 cells after 4 days	[PMID: 17475370]
L6	IC₅₀	147 μM Compound: miltefosine	Cytotoxicity against rat L6 cells Cytotoxicity against rat L6 cells	[PMID: 18989953]
L6	IC₅₀	58.4 μM Compound: miltefosine	Toxicity against rat L6 cells Toxicity against rat L6 cells	[PMID: 19781948]
L6	IC₅₀	0.25 μM Compound: Miltefosine	Antileishmanial activity against Leishmania donovani infected in rat L6 cells Antileishmanial activity against Leishmania donovani infected in rat L6 cells	[PMID: 19942439]
L6	IC₅₀	0.37 μM Compound: Miltefosine	Antiparasitic activity against amastigotes of Leishmania donovani MHOM/ET/67/L82 infected in rat L6 cells after 72 hrs by by Alamar blue assay Antiparasitic activity against amastigotes of Leishmania donovani MHOM/ET/67/L82 infected in rat L6 cells after 72 hrs by by Alamar blue assay	[PMID: 21937228]
L6	IC₅₀	0.44 μM Compound: Miltefosine	Antileishmanial activity against Leishmania donovani MHOM-ET-67/L82 amastigotes infected in rat L6 cells after 72 hrs by alamar blue assay Antileishmanial activity against Leishmania donovani MHOM-ET-67/L82 amastigotes infected in rat L6 cells after 72 hrs by alamar blue assay	[PMID: 22023653]
L6	IC₅₀	0.19 μg/mL Compound: Miltefosine	Antileishmanial activity against axenic amastigote stage of Leishmania donovani MHOM/ET/67/L82 infected in rat L6 cells after 72 hrs by alamar blue assay Antileishmanial activity against axenic amastigote stage of Leishmania donovani MHOM/ET/67/L82 infected in rat L6 cells after 72 hrs by alamar blue assay	[PMID: 22352841]
L6	IC₅₀	143.1 μM Compound: Miltefosine	Cytotoxicity against rat L6 cells assessed as growth inhibition after 72 hrs by inverted microscopy Cytotoxicity against rat L6 cells assessed as growth inhibition after 72 hrs by inverted microscopy	[PMID: 23153330]
L6	IC₅₀	143 μM Compound: Miltefosine	Cytotoxicity against rat L6 cells after 72 hrs by alamar blue assay Cytotoxicity against rat L6 cells after 72 hrs by alamar blue assay	[PMID: 26237241]
L6	IC₅₀	137 μM Compound: Miltefosine	Cytotoxicity against rat L6 cells assessed as growth inhibition after 72 hrs by alamar blue assay Cytotoxicity against rat L6 cells assessed as growth inhibition after 72 hrs by alamar blue assay	[PMID: 28284860]
L6	CC₅₀	137 μM Compound: MF	Cytotoxicity against rat L6 cels assessed as reduction in cell viability after 72 hrs by Alamar Blue dye-based fluorometric analysis Cytotoxicity against rat L6 cels assessed as reduction in cell viability after 72 hrs by Alamar Blue dye-based fluorometric analysis	[PMID: 30615444]
L6	IC₅₀	137 μM Compound: Miltefosine	Cytotoxicity against rat L6 cells assessed as reduction in cell viability measured after 72 hrs by Alamar blue based inverted microscopy analysis Cytotoxicity against rat L6 cells assessed as reduction in cell viability measured after 72 hrs by Alamar blue based inverted microscopy analysis	[PMID: 31784198]
L929	IC₅₀	241.4 μM Compound: MT	Cytotoxicity against mouse NCTC-929 cells after 72 hrs by MTT assay Cytotoxicity against mouse NCTC-929 cells after 72 hrs by MTT assay	[PMID: 28881289]
L929	CC₅₀	119.7 μM Compound: Milt	Cytotoxicity against mouse NCTC clone 929 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay Cytotoxicity against mouse NCTC clone 929 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay	[PMID: 37484568]
LLC-MK2	IC₅₀	122 μM Compound: Miltefosine	Cytotoxicity against rhesus monkey LLC-MK2 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against rhesus monkey LLC-MK2 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 25924111]
Macrophage	IC₅₀	36 μM Compound: Miltefosine	Cytotoxicity against human PMA-differentiated THP-1 macrophages assessed as inhibition of cell growth by MTT assay Cytotoxicity against human PMA-differentiated THP-1 macrophages assessed as inhibition of cell growth by MTT assay	[PMID: 35434631]
MCF7	IC₅₀	39.2 μM Compound: HPC, miltefosine	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 19762125]
MCF7	IC₅₀	42.3 μM Compound: miltefosine	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 20039643]
MCF7	IC₅₀	11.4 μM Compound: 1, HePC, Miltex, Impavido	Cytotoxicity against human MCF7 cells after 24 hrs by FACS analysis Cytotoxicity against human MCF7 cells after 24 hrs by FACS analysis	[PMID: 22138309]
MCF7	IC₅₀	11.4 μM Compound: 1, HePC	Cytotoxicity against human MCF7 cells by flow cytometric analysis Cytotoxicity against human MCF7 cells by flow cytometric analysis	[PMID: 23415083]
MCF7	IC₅₀	18.9 μM Compound: HPC	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 23792315]
MCF7	IC₅₀	34.7 μM Compound: Miltefosine	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 18 hrs followed by MTT addition for 4 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 18 hrs followed by MTT addition for 4 hrs by MTT assay	[PMID: 25128666]
MCF7	IC₅₀	35.68 μM Compound: HPC, miltefosine	Cytotoxicity against human MCF7 cells after 24 hrs by MTT method Cytotoxicity against human MCF7 cells after 24 hrs by MTT method	[PMID: 25698517]
MCF7	IC₅₀	9.2 μM Compound: Miltefosine	Cytotoxic activity against human MCF7 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay Cytotoxic activity against human MCF7 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay	[PMID: 25814031]
MDA-MB-231	IC₅₀	37.6 μM Compound: HPC, miltefosine	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 19762125]
MDA-MB-231	IC₅₀	34.8 μM Compound: HPC	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 23792315]
MDA-MB-231	IC₅₀	2.075 μM Compound: Miltefosine	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation incubated for 18 hrs followed by MTT addition for 4 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation incubated for 18 hrs followed by MTT addition for 4 hrs by MTT assay	[PMID: 25128666]
MDA-MB-435	IC₅₀	23 μM Compound: HePC	Cytotoxicity against human MDA-MB-435 cells after 3 days in serum free conditions by MTT assay Cytotoxicity against human MDA-MB-435 cells after 3 days in serum free conditions by MTT assay	[PMID: 16279790]
MDA-MB-435	IC₅₀	5 μM Compound: HePC	Inhibition of Akt phosphorylation in MDA-MB-435 cells after 2 hrs Inhibition of Akt phosphorylation in MDA-MB-435 cells after 2 hrs	[PMID: 16279790]
MES-SA/Dx5	IC₅₀	5.35 μM Compound: miltefosine	In vitro cytotoxic activity against uterine sarcoma (MES-SA) cells assayed by inhibition of [3H]-labeled thymidine incorporation In vitro cytotoxic activity against uterine sarcoma (MES-SA) cells assayed by inhibition of [3H]-labeled thymidine incorporation	[PMID: 11728191]
MRC5	CC₅₀	24.7 μM Compound: Miltefosine	Cytotoxicity against human MRC5 SV2 cells assessed as reduction in cell growth after 3 days by resazurin staining based fluorometry Cytotoxicity against human MRC5 SV2 cells assessed as reduction in cell growth after 3 days by resazurin staining based fluorometry	[PMID: 26571076]
MRC5	IC₅₀	>50 μM Compound: Miltefosine	Cytotoxicity against human MRC5 cells after 24 hrs by redox-sensitive dye based fluorescent assay Cytotoxicity against human MRC5 cells after 24 hrs by redox-sensitive dye based fluorescent assay	[PMID: 33091607]
MRC5	CC₅₀	36.8 μM Compound: Miltefosine	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability measured after 96 hrs by resazurin assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability measured after 96 hrs by resazurin assay	[PMID: 33148491]
MRC5	CC₅₀	>64 μM Compound: Miltefosine	Cytotoxicity against human MRC5 cells measured after 3 days by resazurin staining based fluorometric analysis Cytotoxicity against human MRC5 cells measured after 3 days by resazurin staining based fluorometric analysis	[PMID: 34711050]
NCI-H460	IC₅₀	6.62 μM Compound: miltefosine	In vitro cytotoxic activity against nonsmall cell lung carcinoma (NCI-H460) cells assayed by inhibition of [3H]-labeled thymidine incorporation In vitro cytotoxic activity against nonsmall cell lung carcinoma (NCI-H460) cells assayed by inhibition of [3H]-labeled thymidine incorporation	[PMID: 11728191]
OVCAR-3	IC₅₀	>30 μM Compound: Hexadecylphosphocholine	Inhibitory activity against OVCAR-3 cell growth Inhibitory activity against OVCAR-3 cell growth	[PMID: 8691486]
PC-3	IC₅₀	19.9 μM Compound: Miltefosine	Antiproliferative activity against human PC3 cells assessed as inhibition of cell proliferation incubated for 18 hrs followed by MTT addition for 4 hrs by MTT assay Antiproliferative activity against human PC3 cells assessed as inhibition of cell proliferation incubated for 18 hrs followed by MTT addition for 4 hrs by MTT assay	[PMID: 25128666]
Peritoneal macrophage	CC₅₀	143.5 μM Compound: Miltefosine	Cytotoxicity against mouse peritoneal macrophages after 72 hrs by MTT assay Cytotoxicity against mouse peritoneal macrophages after 72 hrs by MTT assay	[PMID: 28433512]
Peritoneal macrophage	EC₅₀	40.66 μM Compound: Milte	Cytotoxicity against BALB/c mouse peritoneal macrophages after 48 hrs by MTT assay Cytotoxicity against BALB/c mouse peritoneal macrophages after 48 hrs by MTT assay	[PMID: 28826085]
Peritoneal macrophage	CC₅₀	20.3 μM Compound: Miltefosine	Cytotoxicity against BALB/c mouse peritoneal macrophages incubated for 48 hrs by MTT assay Cytotoxicity against BALB/c mouse peritoneal macrophages incubated for 48 hrs by MTT assay	[PMID: 31098003]
Peritoneal macrophage	CC₅₀	131.9 μM Compound: Miltefosine	Cytotoxicity against sodium thioglycolate-stimulated BALB/c mouse peritoneal macrophages measured after 72 hrs Cytotoxicity against sodium thioglycolate-stimulated BALB/c mouse peritoneal macrophages measured after 72 hrs	[PMID: 31605866]
Peritoneal macrophage	CC₅₀	169.49 μM Compound: Miltefosine	Cytotoxicity against BALB/c mouse peritoneal macrophages assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against BALB/c mouse peritoneal macrophages assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 34427442]
Peritoneal macrophage	CC₅₀	96.5 μM Compound: Miltefosine	Cytotoxicity against BALB/c mouse peritoneal macrophages assessed as reduction in cell viability incubated for 72 hrs by resazurin dye based fluorescence assay Cytotoxicity against BALB/c mouse peritoneal macrophages assessed as reduction in cell viability incubated for 72 hrs by resazurin dye based fluorescence assay	[PMID: 34531949]
Peritoneal macrophage	CC₅₀	33 μM Compound: Miltefosine	Cytotoxicity against mouse primary peritoneal macrophages measured after 3 days by resazurin staining based fluorometric analysis Cytotoxicity against mouse primary peritoneal macrophages measured after 3 days by resazurin staining based fluorometric analysis	[PMID: 34711050]
Peritoneal macrophage	IC₅₀	75.3 μM Compound: miltefosine	Cytotoxicity against mouse Peritoneal macrophages cells after 72 hrs by MTS assay Cytotoxicity against mouse Peritoneal macrophages cells after 72 hrs by MTS assay	[PMID: 22989363]
Peritoneal macrophage	CC₅₀	15.8 μM Compound: Miltefosine	Cytotoxicity against Swiss mouse peritoneal macrophages at 20 uM after 5 days by MTT assay Cytotoxicity against Swiss mouse peritoneal macrophages at 20 uM after 5 days by MTT assay	[PMID: 23851117]
Peritoneal macrophage	CC₅₀	33.1 μM Compound: Miltefosine	Cytotoxicity against mouse primary peritoneal macrophages assessed as reduction in cell growth after 3 days by resazurin staining based fluorometry Cytotoxicity against mouse primary peritoneal macrophages assessed as reduction in cell growth after 3 days by resazurin staining based fluorometry	[PMID: 26571076]
RAW264.7	IC₅₀	20 μM Compound: miltefosine	Cytotoxicity against mouse RAW264.7 cells after 72 hrs by MTS assay Cytotoxicity against mouse RAW264.7 cells after 72 hrs by MTS assay	[PMID: 22989363]
RAW264.7	IC₅₀	10.23 μM Compound: Miltefosine	Antikinetoplastid activity against Leishmania donovani LV9 axenic amastigotes in mouse RAW264.7 cells assessed as viability measured 24 hrs by SYBR green assay Antikinetoplastid activity against Leishmania donovani LV9 axenic amastigotes in mouse RAW264.7 cells assessed as viability measured 24 hrs by SYBR green assay	[PMID: 25499437]
RAW264.7	IC₅₀	0.73 μM Compound: Miltefosine	Antileishmanial activity against Leishmania donovani MHOM/ET/67/HU3 amastigotes infected in mouse RAW264.7 cells assessed as growth inhibition after 48 hrs by SYBR green 1 staining based fluorescence assay Antileishmanial activity against Leishmania donovani MHOM/ET/67/HU3 amastigotes infected in mouse RAW264.7 cells assessed as growth inhibition after 48 hrs by SYBR green 1 staining based fluorescence assay	[PMID: 26774924]
RAW264.7	CC₅₀	>100 μM Compound: Miltefosine	Cytotoxicity against mouse RAW264.7 cells assessed as cell growth inhibition after 72 hrs by Alamar blue dye-based assay Cytotoxicity against mouse RAW264.7 cells assessed as cell growth inhibition after 72 hrs by Alamar blue dye-based assay	[PMID: 27793448]
RAW264.7	IC₅₀	44.78 μM Compound: Milte	Cytotoxicity against mouse RAW264.7 cells after 48 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells after 48 hrs by MTT assay	[PMID: 28826085]
RAW264.7	CC₅₀	43.01 μM Compound: Miltefosine	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell growth measured after 48 hrs by SYBR Green 1 dye based fluorescence assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell growth measured after 48 hrs by SYBR Green 1 dye based fluorescence assay	[PMID: 33148491]
RAW264.7	CC₅₀	21.84 μM Compound: Miltefosine	Cytotoxicity against mouse RAW264.7 cells measured after 48 hrs Cytotoxicity against mouse RAW264.7 cells measured after 48 hrs	[PMID: 38964519]
RBL-2H3	IC₅₀	4.6 μM Compound: 6	Inhibition of rat RBL2H3 cell granulation assessed as reduction of beta hexasaminidase release Inhibition of rat RBL2H3 cell granulation assessed as reduction of beta hexasaminidase release	[PMID: 20153565]
RBL-2H3	IC₅₀	4.6 μM Compound: 1	Inhibition of anti-DNP-IgE-induced degranulation in rat RBL2H3 cells assessed as beta-hexosaminidase release after 30 mins by fluorescence assay Inhibition of anti-DNP-IgE-induced degranulation in rat RBL2H3 cells assessed as beta-hexosaminidase release after 30 mins by fluorescence assay	[PMID: 21421276]
THP-1	IC₅₀	28.603 μM Compound: 13, miltefosine	Cytotoxicity against human THP1 cells after 72 hrs Cytotoxicity against human THP1 cells after 72 hrs	[PMID: 17158053]
THP-1	IC₅₀	28.6 μM Compound: miltefosine	Cytotoxicity against human THP1 cells after 72 hrs Cytotoxicity against human THP1 cells after 72 hrs	[PMID: 18220332]
THP-1	CC₅₀	28.6 μM Compound: Miltefosine	Cytotoxicity against human THP1 cells after 48 hrs by propidium iodide and SYBR14 satining-base flow cytometry Cytotoxicity against human THP1 cells after 48 hrs by propidium iodide and SYBR14 satining-base flow cytometry	[PMID: 19926293]
THP-1	IC₅₀	2.7 μM Compound: Miltefosine	Antileishmanial activity against Leishmania infantum A1 amastigotes infected in human THP1 cells assessed as reduction in intracellular parasite load after 48 hrs by Giemsa staining Antileishmanial activity against Leishmania infantum A1 amastigotes infected in human THP1 cells assessed as reduction in intracellular parasite load after 48 hrs by Giemsa staining	[PMID: 19926293]
THP-1	IC₅₀	2.56 μM Compound: miltefosine	Antileishmanial activity against intracellular amastigote form of Leishmania infantum MK-1 infected in human THP1 cells after 48 hrs using giemsa staining Antileishmanial activity against intracellular amastigote form of Leishmania infantum MK-1 infected in human THP1 cells after 48 hrs using giemsa staining	[PMID: 20719503]
THP-1	IC₅₀	28.6 μM Compound: miltefosine	Cytotoxicity against human THP1 cells using propidium iodide and SYBR-14 staining after 72 hrs by flow cytometry Cytotoxicity against human THP1 cells using propidium iodide and SYBR-14 staining after 72 hrs by flow cytometry	[PMID: 20719503]
THP-1	IC₅₀	6.7 μM Compound: miltefosine	Antileishmanial activity against intracellular amastigote form of Leishmania infantum MON 235 infected in human THP1 cells after 48 hrs using giemsa staining Antileishmanial activity against intracellular amastigote form of Leishmania infantum MON 235 infected in human THP1 cells after 48 hrs using giemsa staining	[PMID: 20719503]
THP-1	IC₅₀	18.5 μM Compound: Miltefosine	Cytotoxicity against human THP1 cells assessed as live cells in neubauer chamber after 24 hrs by trypan blue assay Cytotoxicity against human THP1 cells assessed as live cells in neubauer chamber after 24 hrs by trypan blue assay	[PMID: 21571403]
THP-1	IC₅₀	7 μM Compound: MLF	Cytotoxicity against PMA-stimulated human THP1 cells after 72 hrs by MTT assay Cytotoxicity against PMA-stimulated human THP1 cells after 72 hrs by MTT assay	[PMID: 22939695]
THP-1	IC₅₀	18.5 μM Compound: Miltefosine	Cytotoxicity against human THP1 cells after 24 hrs by propidium iodide staining-based flow cytometric analysis Cytotoxicity against human THP1 cells after 24 hrs by propidium iodide staining-based flow cytometric analysis	[PMID: 24448421]
THP-1	CC₅₀	18.9 μM Compound: Miltefosine	Cytotoxicity against human THP1 cells infected with intracellular amastigote stage of Leishmania donovani MHOM/ET/67/HU3 Cytotoxicity against human THP1 cells infected with intracellular amastigote stage of Leishmania donovani MHOM/ET/67/HU3	[PMID: 25036797]
THP-1	EC₅₀	11.1 μM Compound: Miltefosine	Antileishmanial activity against extracellular promastigote stage of Leishmania donovani MHOM/ET/67/HU3 infected in human THP1 cells incubated for 28 hrs followed by additional 20 hrs incubation by confocal microscopy Antileishmanial activity against extracellular promastigote stage of Leishmania donovani MHOM/ET/67/HU3 infected in human THP1 cells incubated for 28 hrs followed by additional 20 hrs incubation by confocal microscopy	[PMID: 25036797]
THP-1	EC₅₀	4.83 μM Compound: Miltefosine	Antileishmanial activity against intracellular amastigote stage of Leishmania donovani MHOM/ET/67/HU3 infected in human THP1 cells after 3 days by confocal microscopy Antileishmanial activity against intracellular amastigote stage of Leishmania donovani MHOM/ET/67/HU3 infected in human THP1 cells after 3 days by confocal microscopy	[PMID: 25036797]
THP-1	EC₅₀	0.88 μM Compound: Miltefosine	Anti-leishmanial activity against Leishmania donovani MHOM/IND/80/Dd8 amastigotes infected in human THP1 cells incubated for 72 hrs at 37 degC by DAPI staining based assay Anti-leishmanial activity against Leishmania donovani MHOM/IND/80/Dd8 amastigotes infected in human THP1 cells incubated for 72 hrs at 37 degC by DAPI staining based assay	[PMID: 25462252]
THP-1	EC₅₀	10.61 μM Compound: Miltefosine	Anti-leishmanial activity against Leishmania major MHOM/JL/80/ Friedlin amastigotes infected in human THP1 cells incubated for 72 hrs at 37 degC by DAPI staining based assay Anti-leishmanial activity against Leishmania major MHOM/JL/80/ Friedlin amastigotes infected in human THP1 cells incubated for 72 hrs at 37 degC by DAPI staining based assay	[PMID: 25462252]
THP-1	EC₅₀	26.86 μM Compound: Miltefosine	Cytotoxicity against human THP1 cells after 48 hrs by MTT assay Cytotoxicity against human THP1 cells after 48 hrs by MTT assay	[PMID: 25462252]
THP-1	IC₅₀	6.8 μM Compound: Miltefosine	Antileishmanial activity against Leishmania donovani MHOM/IN/00/DEVI intracellular amastigotes infected in human THP1 cells assessed as reduction in parasite-infected macrophages incubated for 120 hrs by Giemsa staining based microscopy Antileishmanial activity against Leishmania donovani MHOM/IN/00/DEVI intracellular amastigotes infected in human THP1 cells assessed as reduction in parasite-infected macrophages incubated for 120 hrs by Giemsa staining based microscopy	[PMID: 25559208]
THP-1	IC₅₀	81.28 μM Compound: HPC, miltefosine	Cytotoxicity against human THP1 cells after 24 hrs by MTS method Cytotoxicity against human THP1 cells after 24 hrs by MTS method	[PMID: 25698517]
THP-1	IC₅₀	40.5 μM Compound: Miltefosine	Cytotoxicity against human THP1 cells after 72 hrs by MTT assay Cytotoxicity against human THP1 cells after 72 hrs by MTT assay	[PMID: 25846065]
THP-1	IC₅₀	6.8 μM Compound: Miltefosine	Antileishmanial activity against intracellular amastigote stage of Leishmania donovani MHOM/IN/00/DEVI infected in human THP1 cells assessed as decrease infected macrophages after 120 hrs by microscopy Antileishmanial activity against intracellular amastigote stage of Leishmania donovani MHOM/IN/00/DEVI infected in human THP1 cells assessed as decrease infected macrophages after 120 hrs by microscopy	[PMID: 25846065]
THP-1	IC₅₀	31.5 μM Compound: Miltefosine	Cytotoxicity against differentiated human THP-1 cells measured after 48 hrs by MTT assay Cytotoxicity against differentiated human THP-1 cells measured after 48 hrs by MTT assay	[PMID: 26791014]
THP-1	IC₅₀	54.08 μM Compound: Miltefosine	Cytotoxicity against human PMA-differentaited THP1 cells after 24 hrs by MTT assay Cytotoxicity against human PMA-differentaited THP1 cells after 24 hrs by MTT assay	[PMID: 28359789]
THP-1	CC₅₀	15 μM Compound: MIL	Cytotoxicity against human THP1 cells assessed as decrease in viable cells after 72 hrs by MTT assay Cytotoxicity against human THP1 cells assessed as decrease in viable cells after 72 hrs by MTT assay	[PMID: 29407968]
THP-1	EC₅₀	19 μM Compound: Miltefosine	Cytotoxicity against human THP1 cells assessed as reduction in cell viability after 24 hrs by propidium iodide staining based fluorescence microscopic analysis Cytotoxicity against human THP1 cells assessed as reduction in cell viability after 24 hrs by propidium iodide staining based fluorescence microscopic analysis	[PMID: 29501944]
THP-1	CC₅₀	>40 μM Compound: Miltefosine	Cytotoxicity against human THP1 cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against human THP1 cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 29885575]
THP-1	CC₅₀	>40 μM Compound: Miltefosine	Cytotoxicity against human THP1 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human THP1 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30092366]
THP-1	IC₅₀	15.85 μM Compound: Miltefosine	Cytotoxicity against human THP1 cells infected with Leishmania donovani MHOM/SD/62/1S-CL2D LdBOB amastigotes harboring eGFP assessed as reduction in cell number after 96 hrs by DAPI staining based microscopic analysis Cytotoxicity against human THP1 cells infected with Leishmania donovani MHOM/SD/62/1S-CL2D LdBOB amastigotes harboring eGFP assessed as reduction in cell number after 96 hrs by DAPI staining based microscopic analysis	[PMID: 30100019]
THP-1	EC₅₀	4.67 μM Compound: Miltefosine	Cytotoxicity against human THP-1 cells Cytotoxicity against human THP-1 cells	[PMID: 30234295]
THP-1	CC₅₀	>40 μM Compound: Miltefosine	Cytotoxicity against human THP1 cells after 72 hrs by MTT assay Cytotoxicity against human THP1 cells after 72 hrs by MTT assay	[PMID: 30655943]
THP-1	EC₅₀	26.86 μM Compound: Miltefosine	Cytotoxicity against human THP1 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human THP1 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31425910]
THP-1	EC₅₀	26.25 μM Compound: MIL	Cytotoxicity against human THP1 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human THP1 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31702921]
THP-1	IC₅₀	2.4 μM Compound: Miltefosine	Antileishmanial activity against intracellular amastigote stage of Leishmania infantum MHOM/MA/67/ITMAP-263 infected in THP1 cells after 120 hrs by giemsa-staining based inverted microscopic mehod Antileishmanial activity against intracellular amastigote stage of Leishmania infantum MHOM/MA/67/ITMAP-263 infected in THP1 cells after 120 hrs by giemsa-staining based inverted microscopic mehod	[PMID: 32073851]
THP-1	IC₅₀	18.5 μM Compound: Miltefosine	Cytotoxicity against human THP1 cells assessed as reduction in cell viability measured after 24 hrs by propidium iodide staining based flow cytometry Cytotoxicity against human THP1 cells assessed as reduction in cell viability measured after 24 hrs by propidium iodide staining based flow cytometry	[PMID: 32223141]
THP-1	CC₅₀	35 μM Compound: Miltefosine	Cytotoxicity against human THP-1 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human THP-1 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 32652409]
THP-1	IC₅₀	18.5 μM Compound: 4	Cytotoxicity against human THP-1 cells assessed as inhibition incubated for 24 hrs by flow cytometry assay Cytotoxicity against human THP-1 cells assessed as inhibition incubated for 24 hrs by flow cytometry assay	[PMID: 32668302]
THP-1	IC₅₀	18.5 μM Compound: Miltefosine	Cytotoxicity against human THP-1 cells assessed as reduction in cell viability incubated for 24 hrs Cytotoxicity against human THP-1 cells assessed as reduction in cell viability incubated for 24 hrs	[PMID: 32738977]
THP-1	CC₅₀	60.73 μM Compound: Miltefosine	Cytotoxicity against human THP1 cells assessed as growth inhibition after 120 hrs by Alamar blue dye based fluorometric analysis Cytotoxicity against human THP1 cells assessed as growth inhibition after 120 hrs by Alamar blue dye based fluorometric analysis	[PMID: 33493972]
THP-1	EC₅₀	>25 μM Compound: Miltefosine	Cytotoxicity against human THP-1 cells by LDH assay Cytotoxicity against human THP-1 cells by LDH assay	[PMID: 33945281]
THP-1	CC₅₀	28.8 μM Compound: Miltefosine	Cytotoxicity against human THP-1 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human THP-1 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 35178179]
THP-1	CC₅₀	>20 μM Compound: Miltefosine	Cytotoxicity against human THP-1 cells assessed as cell growth inhibition Cytotoxicity against human THP-1 cells assessed as cell growth inhibition	[PMID: 35810535]
THP-1	CC₅₀	30.88 μM Compound: Miltefosine	Cytotoxicity in human THP-1 cells assessed as reduction in cell viability incubated for 48 hrs hrs by MTT assay Cytotoxicity in human THP-1 cells assessed as reduction in cell viability incubated for 48 hrs hrs by MTT assay	[PMID: 36105326]
THP-1	CC₅₀	25 μM Compound: Miltefosine	Cytotoxicity against human THP-1 cells incubated for 72 hrs by DAPI staining based analysis Cytotoxicity against human THP-1 cells incubated for 72 hrs by DAPI staining based analysis	[PMID: 38461679]
THP-1	EC₅₀	>250 μM Compound: Miltefosine	Cytotoxicity against human THP-1 cells incubated for 72 hrs by alamar blue cell viability assay Cytotoxicity against human THP-1 cells incubated for 72 hrs by alamar blue cell viability assay	[PMID: 39013490]
THP-1	CC₅₀	22.7 μM Compound: Miltefosine	Cytotoxicity against human THP1 cells Cytotoxicity against human THP1 cells	10.1039/C3MD00299C
THP-1	EC₅₀	7.1 μM Compound: Miltefosine	Antileishmanial activity against amastigote stage of Leishmania donovani MHOM/ET/67/HU3 infected in human THP1 cells assessed as parasite clearance after 3 days by Draq5 staining-based confocal microscopic analysis Antileishmanial activity against amastigote stage of Leishmania donovani MHOM/ET/67/HU3 infected in human THP1 cells assessed as parasite clearance after 3 days by Draq5 staining-based confocal microscopic analysis	10.1039/C3MD00299C
U2OS	CC₅₀	11.5 μM Compound: MIL	Cytotoxicity against human U2OS cells assessed as decrease in viable cells after 72 hrs by MTT assay Cytotoxicity against human U2OS cells assessed as decrease in viable cells after 72 hrs by MTT assay	[PMID: 29407968]
Vero	CC₅₀	54.7 μM Compound: Miltefosine	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay	[PMID: 23582274]
Vero	CC₅₀	52.47 μM Compound: Miltefosine	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay	[PMID: 23611626]
Vero	IC₅₀	64.96 μM Compound: Miltefosine	Cytotoxicity against african green monkey Vero cells assessed as growth inhibition after 72 hrs by MTS assay Cytotoxicity against african green monkey Vero cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 23727538]
Vero	IC₅₀	>25 μg/mL Compound: Miltefosine	Cytotoxicity against african green monkey Vero cells after 48 hrs by neutral red Cytotoxicity against african green monkey Vero cells after 48 hrs by neutral red	[PMID: 23891181]
Vero	CC₅₀	54.7 μM Compound: Miltefosine	Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay	[PMID: 23910597]
Vero	CC₅₀	52.74 μM Compound: Miltefosine	Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay	[PMID: 24095747]
Vero	CC₅₀	54.76 μM Compound: MF	Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay	[PMID: 24314395]
Vero	CC₅₀	52.5 μM Compound: Miltefosine	Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay	[PMID: 24635539]
Vero	CC₅₀	52.5 μM Compound: Miltefosine	Cytotoxicity against African green monkey Vero cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 24858541]
Vero	CC₅₀	53.12 μM Compound: MF	Cytotoxicity against African green monkey Vero cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 24900613]
Vero	CC₅₀	52.86 μM Compound: Miltefosine	Cytotoxicity against African green monkey Vero cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 25475205]
Vero	CC₅₀	53.1 μM Compound: MF	Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay	[PMID: 26840364]
Vero	CC₅₀	50.8 μM Compound: miltefosine	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28059524]
Vero	CC₅₀	0.12 μM Compound: Miltefosine	Cytotoxicity against African green monkey Vero cells incubated for 24 to 48 hrs by SRB assay Cytotoxicity against African green monkey Vero cells incubated for 24 to 48 hrs by SRB assay	[PMID: 28645659]
Vero	CC₅₀	99.73 μM Compound: Miltefosine	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by crystal violet staining based assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by crystal violet staining based assay	[PMID: 29656201]
Vero	IC₅₀	21.6 μM Compound: MILT	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by resazurin dye based assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by resazurin dye based assay	[PMID: 30728107]
Vero	IC₅₀	29.6 μM Compound: MILT	Trypanocidal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 amastigotes infected in African green monkey Vero cells after 72 hrs by Giemsa-staining based microscopic assay Trypanocidal activity against Trypanosoma cruzi MHOM/Pe/2011/Arequipa DTU 5 amastigotes infected in African green monkey Vero cells after 72 hrs by Giemsa-staining based microscopic assay	[PMID: 30728107]
Vero	IC₅₀	31.8 μM Compound: MILT	Trypanocidal activity against Trypanosoma cruzi TINF/CH/1956/Tulahuen DTU 6 amastigotes infected in African green monkey Vero cells after 72 hrs by Giemsa-staining based microscopic assay Trypanocidal activity against Trypanosoma cruzi TINF/CH/1956/Tulahuen DTU 6 amastigotes infected in African green monkey Vero cells after 72 hrs by Giemsa-staining based microscopic assay	[PMID: 30728107]
Vero	IC₅₀	39.7 μM Compound: MILT	Trypanocidal activity against Trypanosoma cruzi IRHOD/CO/2008/SN3 DTU 1 amastigotes infected in African green monkey Vero cells after 72 hrs by Giemsa-staining based microscopic assay Trypanocidal activity against Trypanosoma cruzi IRHOD/CO/2008/SN3 DTU 1 amastigotes infected in African green monkey Vero cells after 72 hrs by Giemsa-staining based microscopic assay	[PMID: 30728107]
Vero	CC₅₀	99.73 μM Compound: Miltefosine	Cytotoxicity against African green monkey Vero cells after 72 hrs by crystal violet staining based assay Cytotoxicity against African green monkey Vero cells after 72 hrs by crystal violet staining based assay	[PMID: 31260888]
Vero	CC₅₀	99.7 μM Compound: Miltefosine	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 72 hrs by crystal violet staining based analysis Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 72 hrs by crystal violet staining based analysis	[PMID: 36493614]
Vero	CC₅₀	51.8 μM Compound: Miltefosine	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by MTT assay	[PMID: 36565533]
Vero	CC₅₀	99.73 μM Compound: Miltefosine	Cytotoxicity against green monkey Vero cells incubated for 72 hrs by crystal violet staining analysis Cytotoxicity against green monkey Vero cells incubated for 72 hrs by crystal violet staining analysis	[PMID: 37031526]
Vero	CC₅₀	99.7 μM Compound: Miltefosine	Cytotoxicity against African green monkey Vero cells incubated for 72 hrs by crystal violet staining based assay Cytotoxicity against African green monkey Vero cells incubated for 72 hrs by crystal violet staining based assay	[PMID: 37269671]
Vero	CC₅₀	56.5 μM Compound: Miltefosine	Cytotoxicity against African green monkey Vero cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as cell viability after 72 hrs by MTT assay	10.1039/C4MD00298A
WI-38	IC₅₀	>100 μM Compound: MIL	Cytotoxicity against human WI38 cells after 48 hrs by CellTiter-Glo assay Cytotoxicity against human WI38 cells after 48 hrs by CellTiter-Glo assay	[PMID: 29407968]

In Vitro

Treatment of HIV-1 infected macrophages with Miltefosine inhibits the recruitment of PH-AktGFP to the plasma membrane. Since Miltefosine inhibits Akt through mimicry of the PH domain, it is likely that Miltefosine binds to PIP3, blocking the recruitment of PH-Akt to the membrane^[1]. Miltefosine (HePC) inhibits protein kinase C (PKC) from NIH3T3 cells in cell-free extracts with a IC₅₀ of about 7 μM. Inhibition is competitive with regard to phosphatidylserine with a K_i of 0.59 μM^[2]. Miltefosine is an alkylphospholipid that inhibit activation of Akt. Miltefosine is a direct inhibitor of Akt, and induces dose-dependent inhibition of primary effusion lymphoma (PEL) in culture and also inhibits the downstream targets of Akt, such as mTOR, leading to reduced phosphorylation and activation of S6K and S6. Importantly, Miltefosine also inhibits Akt targets that are not part of the mTOR pathway, eg, FOXO1, and are therefore expected to have a greater therapeutic impact than mTORC1 inhibitors alone^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Mice are randomized into groups of 5 and injected intraperitoneally 5 days a week with 50 mg/kg of either Miltefosine or Perifosine dissolved in PBS, or equivalent volume of vehicle (PBS). Both Miltefosine and Perifosine inhibit the growth rate of tumors compared with vehicle-treated mice. By day 14 after treatment, there is an approximately 50% decrease in average tumor volume in Perifosine- and Miltefosine-treated mice, compared with vehicle-treated mice (P<0.04). Tumor growth is also significantly retarded (P<0.04 for Perifosine and P≤0.055 for Miltefosine by linear mixed-effects model analysis). Immunohistochemical analyses display an overall reduction in staining for phosphorylated ribosomal S6 protein in tumor sections from Miltefosine- and Perifosine-treated mice compared with the PBS-treated mice. This reduced phosphorylation correlated with the delay in tumor progression in drug-treated animals^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Essai clinique

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 58066-85-6
Appearance Solid
Masse moléculaire 407.57
Formule C₂₁H₄₆NO₄P
Color White to off-white
SMILES

O=P(OCC[N+](C)(C)C)(OCCCCCCCCCCCCCCCC)[O-]
Synonyms

HePC; Hexadecyl phosphocholine
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (15)

All Cell Imaging/StainingWBIn Vivo Efficacy StudyHistological Imaging/Staining

Sort by:

Journal Impact Factor

Adv Sci (Weinh)

Mgp High-Expressing MSCs Orchestrate the Osteoimmune Microenvironment of Collagen/Nanohydroxyapatite-Mediated Bone Regeneration. [Abstract]

2024 Jun;11(23):e2308986. PMID: 38588510

Miltefosine purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Jun;11(23):e2308986. [Abstract]

ALP and ARS staining, ARS staining quantification analysis of MGP-overexpressing hBMMSCs treated with inhibitors of PI3K-Akt signaling pathway (Miltefosine (7 μM) and PI3K-IN-1).
Leukemia

A prognostic survival model based on metabolism-related gene expression in plasma cell myeloma. [Abstract]

2021 Nov;35(11):3212-3222. PMID: 33686197
Chin Med

β-elemene promotes microglial M2-like polarization against ischemic stroke via AKT/mTOR signaling axis-mediated autophagy. [Abstract]

2024 Jun 15;19(1):86. PMID: 38879549

Miltefosine purchased from MedChemExpress. Usage Cited in: Chin Med. 2024 Jun 15;19(1):86. [Abstract]

Miltefosine (AKT inhibitor) showed similar regulatory effects as β-elemene, further confirming the efficacy of β-elemene on autophagy by inhibiting AKT.
Eur J Pharmacol

Miltefosine attenuates silicosis involving inhibiting the Akt/mTOR signaling pathway. [Abstract]

2026 May 27:178931. PMID: 42203065
Int Immunopharmacol

CCTα and GVI iPLA2-induced aberrant phosphatidylcholine metabolism contributes to pulmonary inflammation and fibrosis. [Abstract]

2025 May 27:156:114718. PMID: 40286783
Chem Biol Interact

Dimethylsphingosine and miltefosine induce apoptosis in lung adenocarcinoma A549 cells in a synergistic manner. [Abstract]

2019 Sep 1:310:108731. PMID: 31265827
Molecules

In Vitro and in Vivo Activity of mTOR Kinase and PI3K Inhibitors Against Leishmania donovani and Trypanosoma brucei. [Abstract]

2020 Apr 23;25(8):1980. PMID: 32340370

Miltefosine purchased from MedChemExpress. Usage Cited in: Molecules. 2020 Apr 23;25(8):1980. [Abstract]

Groups of animals (five mice per group) were treated with single 30 mg/kg doses of Miltefosine, a vehicle control with PBS, or with Torin2, dactolisib, NVP-BGT226 formulations at 15, 50, and 5 mg/kg, respectively, for 5 days via the oral route.

Miltefosine purchased from MedChemExpress. Usage Cited in: Molecules. 2020 Apr 23;25(8):1980. [Abstract]

Postmortem Giemsa-stained liver smears were obtained from mice after no treatment or exposure to the vehicle, Miltefosine, or mTOR/PI3K compounds at the doses indicated.
J Cell Mol Med

Nicorandil alleviates apoptosis in diabetic cardiomyopathy through PI3K/Akt pathway. [Abstract]

2019 Aug;23(8):5349-5359. PMID: 31131539

Miltefosine purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2019 Aug;23(8):5349-5359. [Abstract]

Western blot analysis of p-eNOS in high glucose-induced H9c2 cardiomyocyte after nicorandil treatment or both nicorandil treatment and PI3K/mTOR inhibitors. N: Nicorandil (100 μmol); MTF: miltefosine (100 μmol); Rapa: rapamycin (100 μmol) NG: normal glucose (5.5 mmol/L); HG: high glucose (25 mmol/L).
Brain Behav Immun Health

Miltefosine as a PPM1A activator improves AD-like pathology in mice by alleviating tauopathy via microglia/neurons crosstalk. [Abstract]

2022 Oct 29:26:100546. PMID: 36388134
Pathogens

Infectivity and Drug Susceptibility Profiling of Different Leishmania-Host Cell Combinations. [Abstract]

2020 May 20;9(5):393. PMID: 32443883
Brain Res

Exacerbation of sensory dysfunction by hematoma-induced circuitry damage in a mouse model of thalamic hemorrhage. [Abstract]

2026 Sep 15:1887:150356. PMID: 42092577
FEBS Lett

Identification of novel anti-leishmanials targeting glutathione synthetase of the parasite: a drug repurposing approach. [Abstract]

2025 Feb;599(3):367-380. PMID: 39266470
J Cell Biochem

Novel chemical scaffold as potential drug against Leishmania donovani: Integrated computational and experimental approaches. [Abstract]

2023 Sep;124(9):1404-1422. PMID: 37566640
Acta Trop

Investigation of anti-leishmanial efficacy of miltefosine and ketoconazole loaded on nanoniosomes. [Abstract]

2018 Sep:185:69-76. PMID: 29733808
Universiteit of Hogeschool

2015.

Solvant et solubilité

In Vitro:

H₂O : 33.33 mg/mL (81.78 mM; ultrasonic and warming and heat to 60°C)

DMSO : 3.33 mg/mL (8.17 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.4536 mL

12.2678 mL

24.5357 mL

5 mM

0.4907 mL

2.4536 mL

4.9071 mL

10 mM

0.2454 mL

1.2268 mL

2.4536 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 100 mg/mL (245.36 mM); Clear solution; Need ultrasonic

Protocole

Kinase Assay^[3]

Levels of enzymatically active caspase-3 are quantified using the ApoAlert Caspase Fluorescent assay kit. Briefly, 1×10⁶ BC-1 PEL cells are treated with 50 μM Miltefosine, 50 μM Perifosine, or 20 nM NVP-BEZ235, as well as the respective vehicle controls. Cells are harvested and lysed 12 hours later. Equivalent micrograms of cell lysate for all samples are incubated with a fluorogenic caspase-3 substrate (DEVD-AFC). Cleavage of DEVD by caspase-3 releases AFC, the fluorescence of which is measured using a FLUOstar OPTIMA fluorometer, with excitation and emission filter wavelengths set to 400 and 505 nm, respectively^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay^[2]

NIH3T3 cells are grown in DMEM supplemented with 10% FCS in a humidified atmosphere of 95% air with 5% CO₂. Cells are plated on 35-mm culture dishes (6-well plates) at 0.5-0.8×10⁵ cells/well. Growth is established for 18-24 h and the cell number of representative wells is determined (time 0). The experiments are started by addition of fresh prepared solution of Miltefosine at given concentrations to the cells or equal volumes of Tris-HCI to control cells. After incubation for 60 h, cells are counted with an electronic counter. Cellular multiplication is calculated^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[3]^[4]

Mice^[3]
PEL cells are washed in ice-cold phosphate buffered saline, counted, and diluted in 100 μL of PBS mixed with 100 μL of growth factor-depleted Matrigel. A total of 1×10⁵ to 7.5×10⁵ BC-1 cells are injected subcutaneously into the right flank of NOD.CB17-Prkdc^scid/J or CB17-Prkdc^scid/J mice. The mice are monitored on alternate days for development of palpable tumors (2 mm³), at which point drug or vehicle treatments are initiated, and are administered either intraperitoneally (Perifosine) or by oral gavage (Rosiglitazone, NVP-BEZ235) 5 days a week. Groups of 5 to 7 mice are used to generate PEL tumors and treated with either vehicle or drug cocktail. Each biologic experiment is repeated multiple times. For Rosiglitazone, 0.25% methylcellulose is used as vehicle, and 30 mg/kg or 60 mg/kg Rosiglitazone is suspended in methylcellulose. For Perifosine and Miltefosine, PBS is used as a vehicle and 50 mg/kg Perifosine or Miltefosine is dissolved in PBS. For NVP-BEZ235, the compound is dissolved in a 1:9 vol/vol mixture of 1-methyl-2-pyrrolidone and polyethylene glycol 300. A dose of 40 mg/kg NVP-BEZ235 or equal volume of the vehicle is administered. Tumor diameters are measured using digital calipers, and tumor volume is calculated. The tumors are excised and fixed in formalin. Statistical analyses are performed using linear model fit by maximum likelihood with individual animals treated as random effect.
Rats^[4]
Male Sprague-Dawley rats (weight 270-290 g) are divided into five groups (n=5). Rats in the treatment groups are administered a single 10 mg/kg oral dose of Miltefosine (MFS) either as an aqueous solution or MFS-LNCs dispersion by gastric gavage. This dose is equivalent to the 20 mg/kg Miltefosine dose administered to mice in the preclinical study after correction for rats. Following administration, blood samples are collected via the orbital plexus under anesthesia at time intervals of 0.5, 1, 2, 4, 7, 10, 24, 48, 72 and 216 h in Eppendorf tubes containing EDTA. Blood samples are then centrifuged immediately at 4000 rpm for 10 min. Plasma samples are frozen and maintained at -80°C pending analysis.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (276 KB)
SDS (644 KB)
- English - EN (644 KB)
- Français - FR (644 KB)
- Deutsch - DE (644 KB)
- Norwegian - NO (644 KB)
- Español - ES (644 KB)
- Swedish - SV (644 KB)
- Italian - IT (644 KB)
- Korean - KR (644 KB)
- Portuguese - PT (644 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Chugh P, et al. Akt inhibitors as an HIV-1 infected macrophage-specific anti-viral therapy. Retrovirology. 2008 Jan 31;5:11 [Content Brief]

[2]. Uberall F, et al. Hexadecylphosphocholine inhibits inositol phosphate formation and protein kinase C activity. Cancer Res. 1991 Feb 1;51(3):807-12. [Content Brief]

[3]. Bhatt AP, et al. Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas. Blood. 2010 Jun 3;115(22):4455-63. [Content Brief]

[4]. Eissa MM, et al. Miltefosine Lipid Nanocapsules for Single Dose Oral Treatment of Schistosomiasis Mansoni: A Preclinical Study. PLoS One. 2015 Nov 17;10(11):e0141788 [Content Brief]

[5]. de Freitas-Junior PR, et al. Effects of miltefosine on the proliferation, ultrastructure, and phospholipid composition of Angomonas deanei, a trypanosomatid protozoan that harbors a symbiotic bacterium. FEMS Microbiol Lett. 2012 Aug;333(2):129-37. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO / H₂O	1 mM	2.4536 mL	12.2678 mL	24.5357 mL	61.3392 mL
DMSO / H₂O	5 mM	0.4907 mL	2.4536 mL	4.9071 mL	12.2678 mL
H₂O	10 mM	0.2454 mL	1.2268 mL	2.4536 mL	6.1339 mL
	15 mM	0.1636 mL	0.8179 mL	1.6357 mL	4.0893 mL
	20 mM	0.1227 mL	0.6134 mL	1.2268 mL	3.0670 mL
	25 mM	0.0981 mL	0.4907 mL	0.9814 mL	2.4536 mL
	30 mM	0.0818 mL	0.4089 mL	0.8179 mL	2.0446 mL
	40 mM	0.0613 mL	0.3067 mL	0.6134 mL	1.5335 mL
	50 mM	0.0491 mL	0.2454 mL	0.4907 mL	1.2268 mL
	60 mM	0.0409 mL	0.2045 mL	0.4089 mL	1.0223 mL
	80 mM	0.0307 mL	0.1533 mL	0.3067 mL	0.7667 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Bioz

Keywords

Miltefosine

15 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Miltefosine

Perifosine

Amphotericin B

Aloxistatin

Paclitaxel

D-Mannose

Cetuximab

Cisplatin

A 922500

Pyrroloquinoline quinone

Vinblastine sulfate

Q-VD-OPh

Daporinad

Publications Citing Use of MedChemExpress (MCE) Miltefosine

Voir tous les produits spécifiques à Isoform Akt

Voir tous les produits spécifiques à Isoform HIV

Voir tous les produits spécifiques à Isoform Parasite

Activité biologique

Chemical Information

Publications (15)

Solvant et solubilité

Protocole

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Bioz

Miltefosine

Perifosine

Amphotericin B

Aloxistatin

Paclitaxel

D-Mannose

Cetuximab

Cisplatin

A 922500

Pyrroloquinoline quinone

Vinblastine sulfate

Q-VD-OPh

Daporinad

Publications Citing Use of MedChemExpress (MCE) Miltefosine

Voir tous les produits spécifiques à Isoform Akt

Voir tous les produits spécifiques à Isoform HIV

Voir tous les produits spécifiques à Isoform Parasite

Activité biologique

Chemical Information

Publications (15)

Solvant et solubilité

Protocole

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Miltefosine Related Classifications

HY-13685 Related Classifications

Bioz